{"pmid":32376603,"title":"Rapid development of an inactivated vaccine candidate for SARS-CoV-2.","text":["Rapid development of an inactivated vaccine candidate for SARS-CoV-2.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 mug or 6 mug per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans.","Science","Gao, Qiang","Bao, Linlin","Mao, Haiyan","Wang, Lin","Xu, Kangwei","Yang, Minnan","Li, Yajing","Zhu, Ling","Wang, Nan","Lv, Zhe","Gao, Hong","Ge, Xiaoqin","Kan, Biao","Hu, Yaling","Liu, Jiangning","Cai, Fang","Jiang, Deyu","Yin, Yanhui","Qin, Chengfeng","Li, Jing","Gong, Xuejie","Lou, Xiuyu","Shi, Wen","Wu, Dongdong","Zhang, Hengming","Zhu, Lang","Deng, Wei","Li, Yurong","Lu, Jinxing","Li, Changgui","Wang, Xiangxi","Yin, Weidong","Zhang, Yanjun","Qin, Chuan","32376603"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 mug or 6 mug per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans."],"journal":"Science","authors":["Gao, Qiang","Bao, Linlin","Mao, Haiyan","Wang, Lin","Xu, Kangwei","Yang, Minnan","Li, Yajing","Zhu, Ling","Wang, Nan","Lv, Zhe","Gao, Hong","Ge, Xiaoqin","Kan, Biao","Hu, Yaling","Liu, Jiangning","Cai, Fang","Jiang, Deyu","Yin, Yanhui","Qin, Chengfeng","Li, Jing","Gong, Xuejie","Lou, Xiuyu","Shi, Wen","Wu, Dongdong","Zhang, Hengming","Zhu, Lang","Deng, Wei","Li, Yurong","Lu, Jinxing","Li, Changgui","Wang, Xiangxi","Yin, Weidong","Zhang, Yanjun","Qin, Chuan"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376603","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/science.abc1932","topics":["Treatment"],"weight":1,"_version_":1666597097311305729,"score":9.490897,"similar":[{"pmid":32434945,"title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","text":["DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.","Science","Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H","32434945"],"abstract":["The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates."],"journal":"Science","authors":["Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434945","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1126/science.abc6284","topics":["Treatment"],"weight":1,"_version_":1667521393700372481,"score":386.90866},{"pmid":32265331,"pmcid":"PMC7157776","title":"Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.","text":["Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.","Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERSMA6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERSMA6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.","mBio","Li, Kun","Li, Zhuo","Wohlford-Lenane, Christine","Meyerholz, David K","Channappanavar, Rudragouda","An, Dong","Perlman, Stanley","McCray, Paul B Jr","He, Biao","32265331"],"abstract":["Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERSMA6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERSMA6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19."],"journal":"mBio","authors":["Li, Kun","Li, Zhuo","Wohlford-Lenane, Christine","Meyerholz, David K","Channappanavar, Rudragouda","An, Dong","Perlman, Stanley","McCray, Paul B Jr","He, Biao"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265331","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1128/mBio.00554-20","keywords":["covid-19","mers","coronavirus","vaccine"],"locations":["Imject"],"e_drugs":["aluminum sulfate"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491985068032,"score":323.87125},{"pmid":32298218,"title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","text":["Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.","Hum Vaccin Immunother","Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena","32298218"],"abstract":["A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses."],"journal":"Hum Vaccin Immunother","authors":["Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298218","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1080/21645515.2020.1740560","keywords":["covid-19","heterologous vaccine","sars","sars-cov-2","coronavirus","receptor-binding domain","subunit vaccine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493250699265,"score":303.59882},{"pmid":32426212,"pmcid":"PMC7231734","title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","text":["Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development.","Cell Rep","Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P","32426212"],"abstract":["The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development."],"journal":"Cell Rep","authors":["Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426212","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.celrep.2020.107725","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728782766083,"score":300.96036},{"pmid":32415260,"title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","text":["Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.","Cell Mol Immunol","Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing","32415260"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable."],"journal":"Cell Mol Immunol","authors":["Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415260","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41423-020-0458-z","keywords":["sars-cov-2","cross-neutralizing antibody","receptor binding motif","spike protein","substitution mutation"],"locations":["vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666991242711400449,"score":294.03754}]}